MDS Pharma Services has launched a new therapeutic focus on metabolic disorders such as diabetes, dyslipidemia, obesity and metabolic syndrome ─conditions that damage the cardiovascular system. The initiative builds on the business unit’s expertise in biomarkers and its experience in managing global clinical trials involving these increasingly prevalent conditions. According to the Centers for Disease Control and Prevention, one-third of the adult population in the U.S. is currently obese,...